Ascendis Pharma revenue and financials
In the fiscal year ended December 2025, Ascendis Pharma reported revenue of €720.13M (+98.03% year over year). The net loss was €228.03M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
How Ascendis Pharma is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 153.0% a year on average over the last 5 years
Compound annual growth rate: from €6.95M in 2020 to €720.13M in 2025.
Revenue has grown for 5 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from −1,097.9% to −18.9%
Operating income over revenue, 2022 → 2025: 1,078.9 percentage points.
Shares outstanding up 19.7% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 0 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 720 | 364 | 267 | 51.2 | 7.8 | 7.0 | 13.4 | 10.6 | 1.5 | 4.6 |
| Cost of revenue | 94.9 | 44.3 | 44.4 | 12.1 | 3.5 | 0.0 | 0.0 | — | — | — |
| Gross profit | 625 | 319 | 222 | 39.0 | 4.3 | 7.0 | 13.4 | 10.6 | 1.5 | 4.6 |
| Selling, general and administrative | 458 | 291 | 264 | 216 | 160 | 76.7 | 48.5 | 25.1 | 13.5 | 11.5 |
| Research and development | 304 | 307 | 413 | 380 | 296 | 261 | 192 | 140 | 99.6 | 66.0 |
| Operating income | -136 | -279 | -456 | -562 | -452 | -331 | -227 | -155 | -112 | -72.9 |
| EBIT | -136 | -279 | -456 | -547 | -452 | -331 | -227 | -155 | -112 | -72.9 |
| EBITDA | -131 | -274 | -437 | -529 | -437 | -321 | -225 | -154 | -111 | -72.2 |
| Interest expense | 207 | 100 | 44.1 | 50.5 | 3.9 | 80.8 | 1.2 | 0.1 | 13.8 | 3.1 |
| Pre-tax income | -213 | -373 | -474 | -578 | -384 | -419 | -218 | -130 | -124 | -68.7 |
| Income tax | 15.4 | 4.8 | 7.3 | 5.4 | -0.4 | -0.2 | -0.2 | -0.4 | -0.5 | -0.2 |
| Net income | -228 | -378 | -481 | -583 | -384 | -419 | -218 | -130 | -124 | -68.5 |
| Net income to common shareholders | -228 | -378 | -481 | -583 | -384 | -419 | -218 | -130 | -124 | -68.5 |
| Basic EPS | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | -3.17 | -3.68 | -2.58 |
| Diluted EPS | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | -3.17 | -3.68 | -2.58 |
| Average shares (basic) | 60.6 | 57.9 | 56.3 | 56.1 | 54.8 | 50.6 | 46.5 | 41.1 | 33.6 | 26.6 |
| Average shares (diluted) | 60.6 | 57.9 | 56.3 | 56.1 | 54.8 | 50.6 | 46.5 | 41.1 | 33.6 | 26.6 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 339 | 247 | 248 | 214 | 158 | 101 | 174 | 57.8 | 36.0 | 95.9 | 138 | 48.0 |
| Cost of revenue | 27.7 | 17.5 | 23.6 | 22.4 | 31.4 | 17.5 | 14.0 | 11.2 | 11.5 | 7.6 | 19.5 | 7.4 |
| Gross profit | 312 | 229 | 224 | 191 | 127 | 83.4 | 160 | 46.6 | 24.5 | 88.3 | 118 | 40.6 |
| Selling, general and administrative | 173 | 145 | 139 | 113 | 108 | 97.6 | 80.2 | 69.8 | 74.3 | 66.8 | 64.0 | 63.6 |
| Research and development | 75.9 | 59.0 | 82.2 | 66.9 | 72.0 | 82.5 | 79.3 | 73.5 | 83.5 | 70.7 | 90.9 | 111 |
| Operating income | 220 | 24.8 | 2.4 | 11.0 | -53.0 | -96.7 | 0.4 | -96.7 | -133 | -49.1 | -36.6 | -134 |
| EBIT | 220 | 24.8 | 2.4 | 11.0 | -53.0 | -96.7 | 0.4 | -96.7 | -133 | -49.1 | -36.6 | -134 |
| EBITDA | 225 | 29.0 | 3.6 | 15.0 | -48.6 | -92.2 | 1.6 | -92.4 | -129 | -44.7 | -35.0 | -130 |
| Interest expense | 14.2 | 67.3 | 74.6 | 66.9 | 33.0 | 44.8 | 14.9 | 25.3 | 19.6 | 77.2 | 68.6 | 24.5 |
| Pre-tax income | 230 | -48.2 | -26.7 | -57.4 | -35.0 | -93.6 | -37.4 | -98.2 | -109 | -129 | -81.1 | -162 |
| Income tax | 23.1 | -678 | 6.9 | 3.6 | 3.8 | 1.1 | 1.1 | 1.0 | 0.2 | 2.5 | 5.8 | 0.6 |
| Net income | 207 | 629 | -33.6 | -61.0 | -38.9 | -94.6 | -38.5 | -99.2 | -109 | -131 | -86.9 | -162 |
| Net income to common shareholders | 207 | 629 | -33.6 | -61.0 | -38.9 | -94.6 | -38.5 | -99.2 | -109 | -131 | -86.9 | -162 |
| Basic EPS | 3.22 | 10.20 | -0.55 | -1.00 | -0.64 | -1.58 | -0.64 | -1.72 | -1.91 | -2.30 | -1.54 | -2.88 |
| Diluted EPS | 2.83 | 9.75 | -0.55 | -1.00 | -0.82 | -1.58 | -0.64 | -1.72 | -1.91 | -2.30 | -1.54 | -2.88 |
| Average shares (basic) | 64.3 | 61.7 | 61.0 | 60.8 | 60.5 | 60.0 | 59.8 | 57.5 | 57.3 | 56.9 | 56.6 | 56.3 |
| Average shares (diluted) | 68.3 | 64.5 | 61.0 | 60.8 | 63.9 | 60.0 | 59.8 | 57.5 | 60.8 | 56.9 | 56.6 | 56.3 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,303 | 1,179 | 826 | 1,090 | 1,090 | 1,085 | 980 | 677 | 319 | 211 |
| Current assets | 1,109 | 1,061 | 703 | 923 | 923 | 806 | 740 | 611 | 293 | 205 |
| Cash and equivalents | 616 | 560 | 392 | 445 | 445 | 446 | 585 | 598 | 278 | 195 |
| Short-term investments | — | 0.0 | 7.3 | 291 | 291 | 236 | 134 | — | — | — |
| Receivables | 158 | 177 | 55.8 | 25.6 | 25.6 | 23.2 | 7.3 | 5.4 | 2.6 | 2.4 |
| Inventory | 302 | 296 | 209 | 131 | 131 | 75.4 | — | — | — | — |
| Net property, plant and equipment | 146 | 98.7 | 111 | 129 | 129 | 126 | 108 | 45.1 | 4.3 | 2.6 |
| Goodwill | 3.5 | 3.5 | 3.5 | — | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| Other intangible assets | 0.2 | 0.5 | 0.9 | 4.8 | 1.3 | 1.8 | 2.2 | — | — | — |
| Long-term investments | 32.5 | 13.6 | 5.7 | 30.4 | 30.4 | 146 | 124 | 15.5 | 17.1 | — |
| Current liabilities | 1,069 | 908 | 737 | 717 | 171 | 100 | 52.8 | 48.0 | 38.9 | 23.8 |
| Accounts payable | 90.7 | 96.4 | 94.6 | 101 | 101 | 59.4 | 21.9 | 27.8 | 19.7 | 17.4 |
| Long-term debt | 720 | 764 | 545 | — | 399 | 105 | — | — | — | — |
| Total debt | 872 | 857 | 644 | 508 | 508 | 105 | 92.0 | 36.6 | — | — |
| Total liabilities | 1,465 | 1,285 | 971 | 826 | 826 | 201 | 141 | 79.6 | 38.9 | 23.8 |
| Total equity (incl. minority) | -163 | -106 | -146 | 263 | 263 | 884 | 839 | 597 | 280 | 187 |
| Retained earnings | -2,700 | -2,560 | -2,277 | -1,860 | — | -1,236 | -1,030 | -611 | -393 | -263 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2,286 | 2,003 | 1,303 | 1,155 | 1,088 | 1,061 | 1,179 | 1,094 | 758 | 803 | 826 | 873 |
| Current assets | 1,390 | 1,122 | 1,109 | 1,018 | 953 | 921 | 1,061 | 974 | 627 | 664 | 703 | 733 |
| Cash and equivalents | 812 | 573 | 616 | 539 | 494 | 518 | 560 | 626 | 259 | 320 | 392 | 441 |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | 7.3 | 14.2 |
| Receivables | 224 | 197 | 158 | 147 | 121 | 76.8 | 177 | 50.4 | 80.7 | 68.7 | 55.8 | 50.0 |
| Inventory | 311 | 314 | 302 | 302 | 303 | 293 | 296 | 265 | 251 | 233 | 209 | 189 |
| Net property, plant and equipment | 136 | 136 | 146 | 102 | 93.5 | 92.4 | 98.7 | 97.5 | 104 | 107 | 111 | 126 |
| Goodwill | — | — | 3.5 | — | — | — | 3.5 | — | — | — | 3.5 | — |
| Other intangible assets | 3.7 | 3.7 | 0.2 | 3.7 | 3.8 | 3.9 | 0.5 | 4.1 | 4.2 | 4.3 | 0.9 | 4.5 |
| Long-term investments | 30.5 | 23.6 | 32.5 | 28.3 | 34.9 | 40.9 | 13.6 | 16.2 | 20.6 | 24.8 | 5.7 | 8.1 |
| Current liabilities | 465 | 1,127 | 1,069 | 986 | 935 | 886 | 908 | 838 | 848 | 799 | 737 | 213 |
| Accounts payable | 104 | 78.6 | 90.7 | 78.6 | 93.7 | 84.4 | 96.4 | 75.3 | 99.5 | 94.5 | 94.6 | 122 |
| Long-term debt | 236 | 257 | 254 | 248 | 255 | 278 | 288 | 264 | 138 | 146 | 138 | 549 |
| Total debt | 450 | 897 | 872 | 814 | 793 | 847 | 857 | 789 | 673 | 669 | — | — |
| Total liabilities | 850 | 1,515 | 1,465 | 1,329 | 1,275 | 1,251 | 1,285 | 1,191 | 1,079 | 1,041 | 971 | 947 |
| Total equity (incl. minority) | 1,436 | 488 | -163 | -174 | -188 | -190 | -106 | -97.3 | -321 | -238 | -146 | -73.4 |
| Retained earnings | -1,878 | -2,084 | -2,700 | -2,697 | -2,666 | -2,658 | -2,560 | -2,547 | -2,474 | -2,391 | -2,277 | -2,204 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 53.9 | -306 | -467 | -496 | -418 | -272 | -176 | -139 | -95.1 | -60.2 |
| Depreciation and amortization | 17.2 | 17.2 | 18.4 | 18.0 | 14.9 | 9.4 | 6.7 | 0.9 | 0.7 | 0.7 |
| Capital expenditure | -8.5 | -1.4 | -2.4 | -14.5 | -23.7 | -19.9 | -5.2 | -2.6 | -0.9 | -0.7 |
| Investing cash flow | -8.5 | 6.9 | 286 | 61.7 | -111 | -291 | -5.2 | -2.6 | -0.9 | -0.7 |
| Financing cash flow | 36.3 | 444 | 134 | 397 | 351 | 603 | 494 | 203 | 125 | 117 |
| Share repurchases | -17.4 | 0.0 | 0.0 | -105 | -21.6 | — | — | — | — | — |
| Debt issued | 0.0 | 134 | 136 | 503 | — | — | — | — | — | — |
| Debt repaid | -22.0 | -11.4 | -10.4 | -6.4 | -6.4 | -4.8 | -4.0 | — | — | — |
| Effect of exchange rates | -25.2 | 22.8 | -6.0 | 35.7 | 38.6 | -53.5 | 7.7 | 20.7 | -13.7 | 4.1 |
| Net change in cash | 56.5 | 167 | -52.6 | -37.2 | -138 | -13.6 | 320 | 82.5 | 15.0 | 60.7 |
| Free cash flow | 45.4 | -308 | -470 | -510 | -441 | — | — | — | — | — |
| Levered free cash flow | 165 | -200 | -333 | — | -282 | -171 | -98.3 | -69.5 | -55.6 | -33.9 |
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 282 | -7.7 | 73.4 | 2.2 | -7.3 | -14.3 | -87.2 | -56.1 | -61.3 | -102 | -42.5 | -125 |
| Depreciation and amortization | 4.6 | 4.2 | 4.3 | 4.0 | 4.3 | 4.5 | 4.0 | 4.4 | 4.4 | 4.5 | 4.5 | 4.7 |
| Capital expenditure | -3.2 | -7.7 | -3.4 | -0.1 | -4.3 | -0.7 | -0.4 | -0.5 | -0.3 | -0.2 | 0.1 | -1.0 |
| Investing cash flow | -2.9 | -6.8 | -3.4 | -0.1 | -4.3 | -0.7 | -0.4 | -0.5 | 0.6 | 7.2 | 6.7 | 22.2 |
| Financing cash flow | -46.1 | -36.8 | 8.5 | 38.9 | 7.0 | -18.0 | 0.1 | 428 | -2.5 | 18.4 | -6.1 | 143 |
| Share repurchases | -56.3 | -59.9 | 0.0 | 0.0 | 0.0 | -28.8 | — | — | — | — | -1.8 | — |
| Debt issued | — | — | 0.0 | — | — | — | 0.0 | 134 | — | — | -3.5 | 140 |
| Debt repaid | -8.1 | -8.6 | -6.8 | -6.6 | -5.5 | -3.1 | -2.9 | -2.8 | -2.8 | -2.8 | -2.7 | -2.6 |
| Effect of exchange rates | 6.7 | 8.1 | -1.6 | 4.1 | -19.2 | -8.6 | 21.5 | -4.4 | 1.6 | 4.1 | -7.2 | 6.2 |
| Net change in cash | 239 | -43.2 | 76.9 | 45.0 | -23.9 | -41.6 | -66.0 | 367 | -61.5 | -71.9 | -49.1 | 47.0 |
| Free cash flow | 278 | -15.4 | 70.0 | 2.1 | -11.7 | -15.0 | -87.6 | -56.6 | -61.7 | -102 | -42.4 | -126 |
| Levered free cash flow | -85.5 | -22.9 | 50.6 | 11.4 | -2.0 | 17.9 | -104 | -31.5 | -55.7 | -53.6 | 58.2 | -88.5 |
Financial statements of similar companies
Companies in the group: same industry, similar size
